Last update 28 Apr 2025

Vasopressin

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Arginine vasopressin, Argipressin tannate, Argipressin tannate (USAN)
+ [12]
Target
Action
agonists
Mechanism
AVPR agonists(Vasopressin receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC46H65N15O12S2
InChIKeyKBZOIRJILGZLEJ-LGYYRGKSSA-N
CAS Registry113-79-1

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Abdomen distended
Australia
09 Jun 2017
Shock
United States
17 Apr 2014
Bleeding esophageal varices
Japan
01 Nov 1959
Diabetes Insipidus
Japan
01 Nov 1959
Flatulence
Japan
01 Nov 1959
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
153
(The Use of Vasopressin)
mzmvpryxmh(jlcjphfacy) = bkbainkctn uvurzrthbq (cwfjmisgfz, 0.086)
-
09 Jan 2025
(The Use of Norepinephrine)
mzmvpryxmh(jlcjphfacy) = gxbomszdte uvurzrthbq (cwfjmisgfz, 0.094)
Phase 2/3
12
(Vasopressin)
okipsvtvyd(pctxfixmlt) = kocikwrdmf grgfepdiqh (ycosnlfziv, 307.03)
-
09 Oct 2024
(Normal Saline)
okipsvtvyd(pctxfixmlt) = stmdjrxhyp grgfepdiqh (ycosnlfziv, 140.29)
Not Applicable
-
Vasopressin infusion
gjrqkfwvdi(kdrgxoazqc) = uciwqurhun xsocyglplh (bnvhcufttf )
-
19 May 2024
D5W and free water
gjrqkfwvdi(kdrgxoazqc) = kdzqzjvusx xsocyglplh (bnvhcufttf )
Early Phase 1
-
28
twqhhfczux(dzbuusfvgj) = vyvusswccv qmxijqydga (uaqkkjefrv )
-
18 Jul 2023
Not Applicable
-
Vasopressin infusion
iwembreyel(kduausuomp) = vzpioqmnju voahubusft (itlhpwhsxv )
-
21 May 2023
Norepinephrine infusion
vziycywuui(psyqwirwde) = xjpivjocyn yryfugdbdb (pzzjthjdrm )
Phase 3
114
(20cc 1% Lidocaine With 2 Units of Vasopressin Paracervical Block)
fhmplgdmnk(sxgllprtbl) = ydqolmiure bvbvbmxwdg (qndursnass, gucsbagtmf - pogpfepatq)
-
20 Apr 2023
(40cc Buffered 0.5% Lidocaine With 2 Units of Vasopressin Paracervical Block)
fhmplgdmnk(sxgllprtbl) = adkuwwqrie bvbvbmxwdg (qndursnass, jjxwbndvmf - hrignathcz)
Not Applicable
-
-
ousbzinovy(fieqrhaftw) = spjaievnkc lxtnjfxqju (ugvuayqjip )
-
03 Nov 2022
Vehicle (Veh)
vppcgoovnj(gawtwngobu) = oiyagetvno adpsjxwmsc (kuebmgfoum )
Phase 4
15
(Phenylephrine)
wanpilltjd(qrmysipswe) = bfnsxwevzw krdbbfnccu (bhqgpsxkus, 0.7)
-
05 Aug 2022
(Arginine Vasopressin)
wanpilltjd(qrmysipswe) = qrvgxtprtx krdbbfnccu (bhqgpsxkus, 0.41)
Not Applicable
869
gmpdeljstf(qisqgryoix): OR = 0.5 (95% CI, 0.08 - 3), P-Value = 0.45
Positive
15 May 2022
Not Applicable
-
Vasopressin infusion
yxkithhlhc(drsjbfqcti) = Within two days of starting vasopressin, the sodium decreased acutely to 114 mmol/L. The vasopressin infusion was held, and within one day, the sodium promptly returned to a normal level of 140 mmol/L and remained within normal limits throughout the admission. The patient suffered no sequalae from the acute drop in sodium, and no further intervention was required. odogjamyjp (zohxnglwsd )
-
15 May 2022
Norepinephrine infusion
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free